Abstract-Increased circulating amino-terminal pro-B-type natriuretic (NT-proBNP) levels are a marker of cardiac dysfunction but also associate with coronary heart disease and stroke. We aimed to investigate whether increased circulating NT-proBNP levels have additive prognostic value for first cardiovascular and cerebrovascular events beyond classic risk factors. In a community-based cohort of 5063 participants free of cardiovascular disease, aged Ն55 years, circulating NT-proBNP levels and cardiovascular risk factors were measured. Participants were followed for the occurrence of first major fatal or nonfatal cardiovascular event. A total of 420 participants developed a first cardiovascular event (108 fatal). After adjustment for classic risk factors, the hazard ratio for cardiovascular events was 2.32 (95% CI: 1.55 to 2.70) in men and 3.08 (95% CI: 1.91 to 3.74) in women for participants with NT-proBNP in the upper compared with the lowest tertile. Corresponding hazard ratios for coronary heart disease, heart failure, and ischemic stroke were 2.01 (95% CI: 1.14 to 2.59), 2.90 (95% CI: 1.33 to 4.34), and 2.06 (95% CI: 0.91 to 3.18) for men and 2.95 (95% CI: 1.30 to 4.55), 5.93 (95% CI: 2.04 to 11.2), and 2.07 (95% CI: 1.00 to 2.97) for women. Incorporation of NT-proBNP in the classic risk model significantly improved the C-statistic both in men and women and resulted in a net reclassification improvement of 9.2% (95% CI: 3.5% to 14.9%; Pϭ0.001) in men and 13.3% (95% CI: 5.9% to 20.8%; PϽ0.001) in women. We conclude that, in an asymptomatic older population, NT-proBNP improves risk prediction not only of heart failure but also of cardiovascular disease in general beyond classic risk factors, resulting in a substantial reclassification of participants to a lower or higher risk category. (Hypertension. 2010;55:00-00.)
T he decision to start treatment in individuals without prevalent cardiac or vascular disease is based on the estimated risk for cardiovascular disease (CVD) using established prediction models, like the Framingham heart or SCORE (systemic coronary risk evaluation) risk function models. 1, 2 A disadvantage of these risk models is that a considerable proportion of individuals without prevalent CVD is classified in an intermediate cardiovascular risk category. In these individuals, the decision to initiate or withhold treatment is not straightforward. To overcome this shortcoming, several biomarkers have been investigated for their additive predictive value for cardiovascular events in the general population beyond the traditional risk models, either by assessing the improvement in C statistic 3 or the reclassification of subjects in different risk categories, 4 however with disappointing results. [5] [6] [7] In the present study we explored whether the addition of amino-terminal pro-B-type natriuretic peptide (NT-proBNP) to a risk model on the basis of classic risk factors improves the accuracy of 10-year cardiovascular risk prediction in an older population and what proportion of individuals at an intermediate risk category could be reclassified in either a lower or higher risk category. NT-proBNP is a cardiac hormone, secreted by cardiomyocytes in response to an increase in ventricular wall stretch. 8 In clinical practice, measurement of NT-proBNP or B-type natriuretic peptide (BNP) plasma levels is routinely applied for the diagnosis and management of subjects with (suspected) heart failure. 9, 10 Moreover, in community-based populations, increased NT-proBNP or BNP plasma levels have been associated with an increased risk for cardiac and noncardiac vascular diseases. 6, 8, [11] [12] [13] [14] [15] Because of these properties and the knowledge that the risk prediction of CVD by classic risk factors is diminished at advancing age, 16 we hypothesized that NT-proBNP may be a useful candidate to improve the accuracy of CVD prediction.
Methods

Setting and Participants
The Rotterdam Study is a prospective cohort study of subjects, aged Ն55 years, living in Rotterdam. Its aim is to investigate the incidence of and risk factors for chronic disabling diseases. Of the 7983 participants recruited in 1990 -1993, 3930 participants had blood sampled at the third examination cycle during [1997] [1998] [1999] . Furthermore, we included 2568 of 3011 participants, additionally recruited and examined in 2000 -2001, fulfilling the same inclusion criteria as the original cohort. After excluding participants with prevalent coronary heart disease, heart failure, and/or stroke, 5211 participants remained. Additionally, 53 participants with an NT-proBNP level above the age-specific cutoff value for the diagnosis of heart failure, as proposed by Januzzi et al 9 (50 to 75 years, 108 pmol/L; Ͼ75 years, 216 pmol/L), were excluded. From these 5158 participants, follow-up was available for all of the end points in 5063 participants (2032 men and 3031 women). A more detailed description of the Rotterdam Study and the collection of data can be found elsewhere. [17] [18] [19] [20] The medical ethics committee of Erasmus Medical Center approved the study.
Risk Factors for CVD
A trained interviewer using a computerized questionnaire collected information on current health status, medical history, and smoking behavior from the subjects of the original cohort (nϭ3930) at the third examination round (1997) (1998) (1999) . From the subjects added to the cohort (nϭ2568), information was collected at their first examination round (2000 -2001) . In addition to the interview, the classic cardiovascular risk factors were measured during 2 visits at the research center. Two blood pressure measurements were taken with a random-0 sphygmomanometer after 5 minutes of rest with the subject in a sitting position. Serum glucose, serum total cholesterol, and high-density lipoprotein cholesterol were measured using standard laboratory techniques. Diabetes mellitus was considered to be present when fasting blood glucose exceeded 7.0 mmol/L, nonfasting glucose exceeded 11.0 mmol/L, and/or antidiabetic medication was used. Hypertension was defined as systolic or diastolic blood pressure of Ն140/90 mm Hg or use of antihypertensive medication. Glomerular filtration rate was estimated using the simplified Modification of Diet in Renal Disease equation. 21 
NT-proBNP Measurement
Blood samples for NT-proBNP measurement were collected in glass tubes containing clot activator and gel for serum separation. The serum was stored at Ϫ80°C. NT-proBNP was measured using a commercially available electrochemiluminescence immunoassay (Elecsys proBNP, F Hoffman-La Roche Ltd) on an Elecsys 2010 analyzer. The precision, analytic sensitivity, and stability characteristics of the system have been described previously. 22 
CVD Monitoring
A history of coronary events was considered present in case of a self-report of coronary event confirmed by ECG or additional clinical information. A validated score for the diagnosis of heart failure, similar to the criteria of the European Society of Cardiology, was used during the interview. 23 A history of stroke was determined by direct interview and subsequent review of general practitioner records of the subjects with a positive history of stroke.
Subjects participating in the Rotterdam Study are monitored continuously for the occurrence of cardiovascular events through automated linkage with the files from general practitioners in the study district. For the diagnosis of cardiac events, 2 research physicians independently coded all of the reported events. In case of disagreement, a decision was made by a medical expert in the field. In case of stroke, events were coded by 2 research physicians and an experienced neurologist. All of the events were coded according to the International Classification of Diseases, 10th Edition. 24 Coronary heart disease was defined as the occurrence of a nonfatal myocardial infarction (International Classification of Diseases, 10th edition code I21), a percutaneous transluminal coronary angioplasty, a coronary artery bypass graft, other forms of acute (I24) or chronic ischemic heart disease (I25), and mortality attributed to coronary artery disease (I20, I21, I24, I25, I46, and R96). Heart failure was defined as incident fatal and nonfatal heart failure (I50). Ischemic stroke was defined as incident fatal and nonfatal ischemic stroke (I63). The composite end point CVD included all of the first events attributed to coronary heart disease, heart failure, or ischemic stroke. Information concerning the vital status of the participants was obtained from the municipal health service of Rotterdam and was available for all of the participants up to January 2007.
Statistical Analysis
Baseline characteristics between men and women were compared using the Student t tests for continuous variables. Categorical data were compared using 2 tests. Calculations on NT-proBNP values were made after logarithmic transformation to correct for its skewed distribution. [11] [12] [13] The additional predictive value of NT-proBNP on top of the classic risk factors age, systolic blood pressure, cholesterol, high-density lipoprotein, smoking (categories: never, former, current), and diabetes mellitus (categories: yes, no) was assessed in 3 steps. The effect of adjustment for Modification of Diet in Renal Disease equation, body mass index, and use of antihypertensives on top of the classic risk factors for the predictive value of NT-proBNP for CVD was also investigated. The results are reported for men and women separately to allow for sex-specific effects.
First, we calculated the hazard ratios (HRs) for cardiovascular events related to a 1-SD increase in logarithmically transformed NT-proBNP. HRs were adjusted for the aforementioned classic risk factors. The HRs were also calculated for the 2 upper, age-corrected tertiles of NT-proBNP, with the first tertile as reference. In the analysis for incident cardiovascular events, subjects were censored at end of follow-up or noncardiovascular death. In the subanalyses for coronary heart disease, heart failure, and stroke, subjects were also censored if a cardiovascular event occurred that was not the end point of that specific analysis. Using likelihood ratio tests, we assessed the improvement of global model fit.
Second, we analyzed the influence of NT-proBNP on the discrimination of the model, that is, the ability to distinguish subjects who will develop disease from subjects who will be free of disease during follow-up, by assessing the change in the C statistic after adding NT-proBNP to a model on the basis of the aforementioned risk factors. All of the reported C statistics were corrected for optimism by bootstrap analysis. 25 The 95% CI around the change in optimismcorrected C statistic was also calculated using bootstrap analysis (1000 bootstrap replicates). 26 Third, as treatment decisions are based using cutoff levels of 10-year risk, reclassification tables were constructed to investigate the number of patients, classified in a higher or lower category of 10-year risk for CVD. Reclassification tables were constructed using 3 different risk categories, that is, 0% to 10%, Ͼ10% to 20%, and Ͼ20%. 3 We used Weibull proportional hazard models to calculate 10-year risk predictions. To evaluate the net percentage of reclassified subjects, we calculated the net reclassification improvement (NRI) on the entire sample, and we evaluated the relative integrative discrimination improvement (RIDI). 4, 27 In additional analyses we tested the predictive value of NT-proBNP over a model including the classic risk factors and C-reactive protein (CRP) in the 2726 subjects in whom CRP was measured. Also, we investigated whether NTproBNP resulted in an improvement of cardiovascular risk prediction in the subjects Ͻ75 years of age. Finally, we investigated whether NT-proBNP predicted the combined end point of coronary heart disease and ischemic stroke. Missing data, Ͻ2% for all of the covariates, were handled using multiple imputation (R library: Hmisc; function: aregImpute). Calibration of the model was assessed using the Hosmer-Lemeshow statistic. 28 Values are presented as meanϮSD or as median with interquartile range. A PϽ0.05 was considered to indicate statistical significance. We used SPSS 15.0 (SPSS Inc) and R 2.7.2 (R Foundation for Statistical Computing) for the statistical analysis.
Results
Baseline characteristics of cohort are shown in Table 1 . The mean age was 67Ϯ8 years in men and 69Ϯ8 years in women. There were small differences between sexes, with a lower systolic blood pressure and a smaller proportion of smokers and diabetics in women ( Table 1 ). The median NT-proBNP level was higher in women than in men (10.2 versus 6.8 pmol/L; PϽ0.001). Follow-up was 9291 years for men and 14 810 years for women. During follow-up, 224 (59 fatal) men and 196 (49 fatal) women experienced a cardiovascular event. Coronary heart disease (nϭ107) was the most frequent cardiovascular event in men followed by heart failure (nϭ60) and ischemic stroke (nϭ54). Incidences of coronary heart disease (nϭ67), heart failure (nϭ59), and ischemic stroke (nϭ70) in women were almost identical.
An increase in the risk for CVD was seen from the lowest to the highest tertile of NT-proBNP after adjustment for the classic risk factors (Figure and Table 3 for HRs with 95% CIs.
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separate end points related to a 1-SD increase in NT-proBNP were coronary heart disease (men: Table 4 ). The improvement of C statistic related to NT-proBNP did not change after including Modification of Diet in Renal Disease equation, body mass index, and use of antihypertensives.
Of the 54 men who experienced an event during follow-up and classified initially in the intermediate risk category, 17 (31.5%) were reclassified to the higher and 4 (7.4%) to the lower risk category using NT-proBNP as risk predictor (Table 5) . Of the 783 men who did not experience an event and were initially classified in the intermediate risk category, 104 (13.3%) were reclassified to the lower and 113 (14.4%) to the higher risk category (Table 5) . Of the 65 women who experienced an event initially classified as having an intermediate risk, 21 (32.2%) were reclassified to the higher and †NT-proBNP model include the covariates of the classic model and NT-proBNP (continuous).
11 (16.9) to the lower risk category (Table 6 ). Of the 867 women without an event in the intermediate risk category, 298 (34.3%) were reclassified to a lower and 136 (15.7) to a higher risk category (Table 6 ). In total, 238 (28%) of 837 men and 466 (50%) of 932 women were reclassified. The NRI of the total sample was 9.2% (95% CI: 3.5% to 14.9%; Pϭ0.001) in men and 13.3% (95% CI: 5.9% to 20.8%; PϽ0.001) in women. The RIDI improved significantly both in men 9.1% (95% CI: 5.0% to 12.9%) and women 16.8% (95% CI: 10.9% to 23.2%).
In subanalysis, including the participants in whom CRP was measured (nϭ2726), CRP did not improve prediction of the classic model, whereas addition of NT-proBNP to a model including the classic risk factors and CRP improved the C statistic from 0. . Because of the lower rate of events after exclusion of heart failure, the NRI decreased to 3.3% (95% CI: Ϫ5.5% to 12.2%) in women and 7.5% (95% CI: 0.0% to 14.7%) in men.
Discussion
In this population-based cohort study, we found that NTproBNP has independent prognostic value for first cardiovascular events beyond the classic risk factors. An increase in the risk not only for heart failure but also for coronary heart disease and ischemic stroke was seen, resulting in a doubling of the risk for first cardiovascular events in subjects with a NT-proBNP above the 80th percentile. Furthermore, NTproBNP improved the prediction of 10-year cardiovascular risk, reflected by an improvement in the C statistic. The addition of NT-proBNP to a model including the classic risk factors improved risk classification, with an NRI of 9% in men and 13% in women. Our findings indicate that the addition of NT-proBNP to a risk model on the basis of the classic risk factors improves the risk prediction of first fatal and nonfatal CVD in healthy older individuals.
In our study, a 1-SD increase in log NT-proBNP was associated with a 47% increase in first fatal and nonfatal cardiovascular events in men and 69% in women after adjustment for classic risk factors. This increase in risk is comparable to what has been found in other population-based studies, adding BNP or NT-proBNP to established risk models. In the Framingham population (mean age: men: 59 years; women: 58 years), a 1-SD increase in log-BNP was associated with a 35% increase in the risk for first cardiovas- For explanation, see legend of Table 5 . Reclassification tables are separated for cases (top) and noncases (bottom) with rows indicating the risk categories based on the classic model without NT-proBNP and columns indicating the new risk stratification after the addition of NT-proBNP to the model. The cells give the No. and percentage of subjects reclassified using Weibull proportional hazards models to estimate 10-year CVD risk.
*For covariates of classic model, see Table 4 . †NT-proBNP model includes the covariates of the classic model and NT-proBNP (continuous).
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Improved Prediction Using NT-proBNP 5 cular events after adjustment for classic risk factors. 29 In a population-based study (mean age: 68 years) from Copenhagen, Denmark, a 1-SD increase in log-NT-proBNP was associated with a 92% increase in the risk for first major cardiovascular events, and in a population-based study (mean age: 71 years) from Uppsala, Sweden, a 1-SD increase in NT-proBNP was associated with a 116% increase in risk for cardiovascular death. 11, 15 More recently, Melander et al showed in a Swedish population (mean age: 58 years) that a 1-SD increase in NT-proBNP related to an increased risk for CVD of 22%. 7 The association of BNP and NT-proBNP with cardiovascular events or overall mortality, together with biomarkers of other pathophysiological pathways, such as CRP, troponin I, and urinary albumin:creatinine ratio, has also been evaluated in population-based studies. 6 -8,11,13,15 Of the 10 biomarkers investigated by Wang et al, 6 BNP had the strongest association with major cardiovascular events. Kistorp et al, 11 evaluating NT-proBNP, CRP, and urinary albumin:creatinine ratio, found that NT-proBNP was the biomarker with the highest risk ratio for first major cardiovascular events, and Zethelius et al, 15 evaluating NT-proBNP, troponin I, CRP, and cystatin C, also found that NT-proBNP had the highest risk ratio for death from cardiovascular causes. In the recent study of Melander et al, 7 NT-proBNP was related to the highest HR for cardiovascular events in comparison with CRP, cystatin C, lipoprotein-associated phospholipase 2, midregional proadrenomedullin, and midregional proatrial natriuretic peptide. These findings indicate that, among the biomarkers tested head to head, B-type natriuretic peptides have the strongest association with CVD.
In our study, increased NT-proBNP levels improved the risk stratification for first cardiovascular events, as evidenced by a significant increase in the C statistic. In most of the previously reported studies, no change in the C statistic for primary cardiovascular events was demonstrated using NT-proBNP as a biomarker. In a study in elderly men with a high prevalence of CVD, an improvement was seen using NT-proBNP in combination with 3 other biomarkers. 15 Also in the study by Melander et al, 7 no improvement in the C statistic or reclassification was found for NT-proBNP for first cardiovascular events, and only a borderline significant improvement of RIDI was found for the prediction of first coronary events.
Several factors may account for these discrepant results between our study and previous studies. First, it is well known that the role of the classic risk factors in cardiovascular risk prediction diminishes with advancing age. 16, 28 As a consequence, the contribution of other factors to risk prediction, like NT-proBNP, may increase. The mean age of the participants in our study was 68 years compared with 59 years for the participants in the Framingham population 6 ; this possibly explains why NT-proBNP improved the C statistic in our study. Second, in the Framingham population, BNP instead of NT-proBNP was tested. NT-proBNP and BNP are released in the circulation in equimolar amounts, but the half-life of NT-proBNP is longer than that of BNP, resulting in more stable circulating levels. The information about the "chronic" cardiovascular condition provided by NT-proBNP may, therefore, be more accurate than that provided by BNP.
In clinical practice, BNP or NT-proBNP is principally used as a biomarker for the diagnosis and management of subjects with (suspected) heart failure. 9, 10 In our population-based study, we found that modestly elevated NT-proBNP levels not only were associated with heart failure but remarkably also with coronary artery disease and ischemic stroke. Apparently, mild elevations of these peptides are present in subjects with an increased risk for heart failure, as well as in subjects with an increased risk for CVD in general. One possible explanation for this intriguing observation is that an increase in BNPs not only occurs in response to myocardial stretch, as in heart failure, but also in response to myocardial ischemia. 30 Especially at an older age, myocardial ischemia is mainly attributed to coronary artery disease, which, in turn, is closely linked to cerebrovascular disease. 31 In primary CVD prevention, decisions regarding medical intervention are guided by the predicted cardiovascular risk. Our findings show that the addition of NT-proBNP resulted in a reclassification of a substantial number of subjects. This still remained after additional adjustment for body mass index and use of blood pressure-lowering agents. From a clinical point of view, accurate risk classification is especially relevant for individuals with an intermediate cardiovascular risk, because the necessity to start or withhold treatment in these subjects is uncertain. Of the 1769 subjects in the intermediate risk category, 28% of men and 50% of women were reclassified, with both in men and women an up-classification of subjects who experienced an event during follow-up. Our findings support the incorporation of biomarkers that reflect subclinical CVD, like NT-proBNP, in risk models on the basis of the classic etiologic risk factors to improve risk prediction.
Limitations
The strength of our study is the availability of NT-proBNP levels in a large number of subjects of a well-characterized cohort with a substantial number of end points, but several limitations have to be mentioned. First, we extrapolated the data to compute 10-year predictions. Second, we performed our analyses in a cohort of subjects Ն55 years of age; it is not justified, therefore, to extrapolate our findings to younger subjects. Because NT-proBNP is a marker of (subclinical) disease, it may predict CVD better in older subjects. Third, CRP was only measured in a subcohort; we found no signification improvement of cardiovascular risk prediction after incorporation of CRP in the classic model. This could be because of a lack of statistical power or because of the decreasing predictive value of CRP in an elderly population. Fourth, we investigated a white population; whether our results can be extrapolated to other ethnic groups requires further investigation. Finally, NT-proBNP was measured only once, and we have no information on the effect of increases or decreases in NT-proBNP levels. The change of NT-proBNP level over time is possibly a better predictor of someone's future cardiovascular risk than a single measurement.
Perspectives
Our study shows that incorporation of NT-proBNP in a traditional risk model improves cardiovascular risk prediction and classification in asymptomatic older subjects. Our study, therefore, lends support to the idea of introducing biomarkers into classic risk models to improve risk prediction of individual subjects. It should be remarked that our findings were obtained in an older population. Especially in older populations, the use of biomarkers for risk prediction is attractive because of the fact that CVD risk prediction by classic risk factors is diminished with advancing age. Introduction of NT-proBNP testing for risk prediction is relatively easy because of the wide-spread availability of this measurement in clinical centers, its low costs, and the lack of requirement for special training of health care providers.
